Your session is about to expire
← Back to Search
Litifilimab for Lupus (EMERALD Trial)
EMERALD Trial Summary
This trial is evaluating the safety and long-term effectiveness of a drug for people with Lupus.
EMERALD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEMERALD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EMERALD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I completed a 52-week study (230LE303 or 230LE304) and attended all required visits.I completed a 52-week trial for litifilimab or placebo and attended all required visits.I am not using experimental or off-label drugs for lupus.My lupus has worsened, needing stronger medication.I'm sorry, I cannot provide a summary for "Key" as it is not a complete screening criterion. Can you please provide me with more information or context?
- Group 1: Litifilimab Low Dose
- Group 2: Litifilimab High Dose
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many patients are being enrolled in this particular experiment?
"The correct answer is that this study, which was first posted on 6/10/2022 and updated on 7/20/2022 according to clinicaltrials.gov, is currently seeking volunteers. In total, 864 individuals are needed for the 62 different sites where the trial will take place."
Are participants still being recruited for this experiment?
"The trial, which was originally posted on June 10th, 2022 and has since been updated, is still recruiting patients according to the information available on clinicaltrials.gov."
What are the side effects of BIIB059?
"There is a fair amount of evidence, from both Phase 3 trials and other sources, that suggests BIIB059 is safe. Therefore, it received a score of 3."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Average response time
- < 1 Day
Typically responds via
Most responsive sites:
- Saint Louis Rheumatology: < 24 hours
Share this study with friends
Copy Link
Messenger